Julian Perez Ronco

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Haifa Kathrin Al‐Ali, Philipp le Coutre, Cornelius F. Waller et al. · Haematologica · 2016 · 158 citations · Full text

Medicine, Hematology, Pharmacology +15

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey

Claire Harrison, Steffen Koschmieder, Lynda Foltz et al. · Annals of Hematology · 2017 · 144 citations · Full text

Medicine, Hematology, Internal Medicine +10

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

Martin Grießhammer, Güray Saydam, Francesca Palandri et al. · Annals of Hematology · 2018 · 60 citations · Full text

Medicine, Hematology, Pharmacology +6

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

Antonio González-Martı́n, Laurence Gladieff, Bengt Tholander et al. · European Journal of Cancer · 2013 · 55 citations

Medicine, Oncology, Pharmacology +12

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, Martin Grießhammer et al. · Blood · 2014 · 32 citations

Medicine, Pharmacology, Pharmacotherapy +4